Understanding the in-home hospice experience for breast cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research focuses on the in-home hospice experience for individuals with unresectable locally advanced or metastatic breast cancer. It involves conducting telehealth check-ins between participants, their caregivers, hospice nurses, and oncology providers to gather insights and improve care. Approximately 200 participants, including patients, caregivers, and healthcare providers, will be involved in the study, which includes verbal consent and a follow-up survey. The study aims to enhance the quality of hospice care through better communication and understanding.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient of any gender with unresectable locally advanced or metastatic breast cancer
* Eligible for in-home hospice services and referred by DFCI clinical team to in-home hospice \</= 1 week before enrollment
* Ability to conduct video or phone check-ins, even if assistance required.
* Able to provide verbal consent with a willingness to take a survey at 4-6 weeks, if medically able
* Hospice setting is within Massachusetts
* Non-English language allowed but interpreter services must be present at each meeting and will be coordinated by scheduling team
* Willingness to provide a caregiver/loved one's contact information for survey contact at 4 weeks after enrollment

Exclusion Criteria:

* Unable to provide verbal consent
* Hospice care planned outside of a home setting (note: if participants start out in a home hospice setting but later transition their hospice care to an inpatient setting, enrollment is allowed as long as they started in a home setting)
* Hospice setting outside of Massachusetts
* Individuals who are under the age of 18, as this is not a project focused on pediatric patients.

Where it's running

• Dana-Farber Cancer Institute
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Claire Smith, MD — Dana-Farber Cancer Institute
• Study coordinator: Claire Smith, MD
• Email: claire_smith@dfci.harvard.edu
• Phone: 617-632-3800

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Capivasertib plus endocrine therapy for HR+/HER2- advanced breast cancer after progression on endocrine treatment

  This trial will test whether adding capivasertib to standard endocrine therapy helps adults with HR+/HER2- advanced or metastatic breast cancer who progressed on prior endocrine treatment stay on treatment longer and maintain quality of life.

  Recruiting at 15 sites Phase 3 Women's Cancer Study Group GmbH · Anderlecht and 15 other locations · NCT07281833

• RLY-2608 plus fulvestrant versus capivasertib plus fulvestrant for PIK3CA‑mutant HR+/HER2‑ advanced breast cancer

  This trial tests whether RLY-2608 combined with fulvestrant works better than capivasertib combined with fulvestrant for adults with HR+/HER2‑ advanced breast cancer that has a PIK3CA mutation and progressed after a CDK4/6 inhibitor.

  Recruiting at 254 sites Phase 3 Relay Therapeutics, Inc. · Gilbert, Arizona and 253 other locations · NCT06982521

• Testing new antibody drugs in advanced breast cancer patients who have used similar treatments before

  This study is testing new antibody drugs to see if they can help advanced breast cancer patients who have already tried similar treatments.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06649331

• Evaluating the effectiveness of sacituzumab govitecan in specific breast cancer patients

  This study is testing if a drug called sacituzumab govitecan can help people with advanced hormone receptor-positive breast cancer who have already been treated with another medication.

  Recruiting at 3 sites Phase 2 Baptist Health South Florida · Miami, Florida and 2 other locations · NCT06263543

• Testing a new drug for advanced solid tumors and breast cancer with specific mutations

  This study is testing a new drug called RLY-2608 to see if it can help people with advanced solid tumors and breast cancer that have specific mutations.

  Recruiting at 36 sites Phase 1 Relay Therapeutics, Inc. · Tucson, Arizona and 36 other locations · NCT05216432

• PRT13722 in advanced HR+/HER2- breast cancer

  This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.

  Recruiting Phase 1 Prelude Therapeutics Incorporated · Maumee, Ohio · NCT07905001

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.